<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-556</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АНАЛИТИЧЕСКИЕ МЕТОДИКИ И МЕТОДЫ КОНТРОЛЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ANALYTICAL AND QUALITY CONTROL METHODS</subject></subj-group></article-categories><title-group><article-title>АНАЛИЗ СТРУКТУРНЫХ ОСОБЕННОСТЕЙ КЕТО-КЕТАЛЬНЫХ ИЗОМЕРОВ ВАРФАРИНА СПЕКТРАЛЬНЫМИ МЕТОДАМИ</article-title><trans-title-group xml:lang="en"><trans-title>ANALYSIS OF STRUCTURAL FEATURES OF THE KETO-KETAL ISOMERS OF WARFARIN BY SPECTRAL METHODS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абышев</surname><given-names>А. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Abyshev</surname><given-names>A. Z.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нгуен</surname><given-names>К. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Nguyen</surname><given-names>K. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зинчук</surname><given-names>Л. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zinchuk</surname><given-names>L. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургская государственная химико-фармацевтическая академия» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St. Petersburg Chemical and Pharmaceutical Academy, Ministry of Healthcare</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>1</issue><fpage>138</fpage><lpage>145</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Абышев А.З., Нгуен К.Б., Зинчук Л.Н., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Абышев А.З., Нгуен К.Б., Зинчук Л.Н.</copyright-holder><copyright-holder xml:lang="en">Abyshev A.Z., Nguyen K.B., Zinchuk L.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/556">https://www.pharmjournal.ru/jour/article/view/556</self-uri><abstract><p>В результате проведённых исследований было показано, что соотношение изомеров при интегрировании в ДМСО-d6 (S,R)-варфарин – (S,S)-варфарин – варфарин с открытой цепью составляют 70:28:2%; в СDCl3 – 45:40:15%. В ИК-спектрах варфарина наблюдаются специфичные полосы поглощения в областях 3271–3277 см-1, 1681–1682 см-1, 1103–1076 см-1, сответствующие νОН, νСН=СН: νas С–О–С. Молекулярный пик варфарина после силирования имеет m/z 380, соответствующий массе триметилсилил-варфарина. Таким образом, показана возможность применения ИК-, ЯМР-спектроскопии и хромато-масс-спектрометрии для подтверждения подлинности производных варфарина.</p></abstract><trans-abstract xml:lang="en"><p>As a result of the studies was shown that the relative ratios of isomers by integration in DMSO-d6: (S, R)-warfarin – (S, S)-warfarin – open chain warfarin are 70%: 28%: 2%; in СDCl3 are 45%: 40%: 15%. In the IR spectra of warfarin specific absorption bands are observed in the regions 3271–3277 cm-1, 1681–1682 cm-1, 1103–1076 cm-1, corresponding to:νOH, νCH=CH: νas C–O–C. The molecular peak of warfarin after silylation has m/z 380 corresponding to the mass of trimethylsilyl-warfarin. Thus, the possibility of using IR, NMR spectroscopy and chromatography-mass spectrometry to confirm the authenticity of warfarin derivatives has been demonstrated.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>варфарин</kwd><kwd>кето-кетальные изомеры</kwd><kwd>ИК-</kwd><kwd>ЯМР-спектроскопия</kwd><kwd>ГХ-МС</kwd></kwd-group><kwd-group xml:lang="en"><kwd>warfarin</kwd><kwd>keto-ketal isomers</kwd><kwd>IR</kwd><kwd>NMR spectroscopy</kwd><kwd>GC-MC</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">А.З. Абышев, Э.М. Агаев, Р.А. Абышев. Природные и снтетические кумарины и флавоноиды. - Баку: Наука и образование, 2014. 482 с.</mixed-citation><mixed-citation xml:lang="en">А.З. Абышев, Э.М. Агаев, Р.А. Абышев. Природные и снтетические кумарины и флавоноиды. - Баку: Наука и образование, 2014. 482 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">M. Wadelius et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose // The pharmacogenomics journal. 2005. V. 5. № 4. P. 262-270.</mixed-citation><mixed-citation xml:lang="en">M. Wadelius et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose // The pharmacogenomics journal. 2005. V. 5. № 4. P. 262-270.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">L. Guasch, M.L. Peach, M.C. Nicklaus. Tautomerism of warfarin: combined chemoinformatics, quantum chemical, and NMR investigation // The Journal of organic chemistry. 2015. V. 80. № 20. P. 9900-9909.</mixed-citation><mixed-citation xml:lang="en">L. Guasch, M.L. Peach, M.C. Nicklaus. Tautomerism of warfarin: combined chemoinformatics, quantum chemical, and NMR investigation // The Journal of organic chemistry. 2015. V. 80. № 20. P. 9900-9909.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">E.J. Valente et al. Structure of warfarin in solution // Journal of medicinal chemistry. 1977. V. 20. № 11. P. 1489-1493.</mixed-citation><mixed-citation xml:lang="en">E.J. Valente et al. Structure of warfarin in solution // Journal of medicinal chemistry. 1977. V. 20. № 11. P. 1489-1493.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">D.A. Barnette et al. Stereospecific Metabolism of R-and S-Warfarin by Human Hepatic Cytosolic Reductases // Drug Metabolism and Disposition. 2017. V. 45. № 9. P. 1000-1007.</mixed-citation><mixed-citation xml:lang="en">D.A. Barnette et al. Stereospecific Metabolism of R-and S-Warfarin by Human Hepatic Cytosolic Reductases // Drug Metabolism and Disposition. 2017. V. 45. № 9. P. 1000-1007.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Martindale: The Complete Drug Reference. 36th Edition / Ed. by S.С. Sweetman. - London: Pharmaceutical Press, 2009. 3694 p.</mixed-citation><mixed-citation xml:lang="en">Martindale: The Complete Drug Reference. 36th Edition / Ed. by S.С. Sweetman. - London: Pharmaceutical Press, 2009. 3694 p.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">M. He et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9 // Archives of biochemistry and biophysics. 1999. V. 372. № 1. P. 16-28.</mixed-citation><mixed-citation xml:lang="en">M. He et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9 // Archives of biochemistry and biophysics. 1999. V. 372. № 1. P. 16-28.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">M.J. Fasco, L.M. Principe. R-and S-Warfarin inhibition of vitamin K and vitamin K 2, 3-epoxide reductase activities in the rat // Journal of Biological Chemistry. 1982. V. 257. № 9. P. 4894-4901.</mixed-citation><mixed-citation xml:lang="en">M.J. Fasco, L.M. Principe. R-and S-Warfarin inhibition of vitamin K and vitamin K 2, 3-epoxide reductase activities in the rat // Journal of Biological Chemistry. 1982. V. 257. № 9. P. 4894-4901.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
